Evidence map›Paper›PMID 34422808›Full record

ArticleFrontiers in cell and developmental biology2021

Comprehensive Analysis of Glycolysis-Related Genes for Prognosis, Immune Features, and Candidate Drug Development in Colon Cancer.

Zhongqi Cui, Guifeng Sun, Ramesh Bhandari, Jiayi Lu, Mengmei Zhang, Rajeev Bhandari, Fenyong Sun, Zhongchen Liu, Shasha Zhao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. BeyondMolecular therapy oncolytics · 2023
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. High expression of glycolysis-relatedJournal of thoracic disease · 2022
    Article
  17. Article
  18. ENO3 promotes colorectal cancer progression by enhancing cell glycolysis.Medical oncology (Northwood, London, England) · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Zhongqi CuiDepartment of Clinical Laboratory, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Guifeng SunDepartment of Clinical Laboratory, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Ramesh BhandariDepartment of Clinical Laboratory, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Jiayi LuDepartment of Clinical Laboratory, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Mengmei ZhangDepartment of Clinical Laboratory, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Rajeev BhandariDepartment of General Surgery, Universal College of Medical Sciences, Bhairahawa, Nepal.
Fenyong SunDepartment of Clinical Laboratory, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Zhongchen LiuDepartment of Gastrointestinal Surgery, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, China.
Shasha ZhaoDepartment of Clinical Laboratory, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Tongji University · CNShanghai Tenth People's Hospital · CNCollege of Medical Sciences · NP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The dysregulated expression of glycolysis-related genes (GRGs) is closely related to the occurrence of diverse tumors and regarded as a novel target of tumor therapy. However, the role of GRGs in colon cancer is unclear. We obtained 226 differential GRGs (DE-GRGs) from The Cancer Genome Atlas (TCGA) database. Cox regression analysis was used to construct a DE-GRG prognostic model, including P4HA1, PMM2, PGM2, PPARGC1A, PPP2CB, STC2, ENO3, and CHPF2. The model could accurately predict the overall survival rate of TCGA and GSE17536 patient cohorts. The risk score of the model was closely related to a variety of clinical traits and was an independent risk factor for prognosis. Enrichment analysis revealed the activation of a variety of glycolysis metabolism and immune-related signaling pathways in the high-risk group. High-risk patients displayed low expression of CD4+ memory resting T cells and resting dendritic cells and high expression of macrophages M0 compared with the expression levels in the low-risk patients. Furthermore, patients in the high-risk group had a higher tumor mutation load and tumor stem cell index and were less sensitive to a variety of chemotherapeutic drugs. Quantitative reverse transcription polymerase chain reaction and immunohistochemistry analyses validated the expression of eight GRGs in 43 paired clinical samples. This is the first multi-omics study on the GRGs of colon cancer. The establishment of the risk model may benefit the prognosis and drug treatment of patients.

Indexed as

chemotherapy responsecolon cancerglycolysisimmune microenvironmentprognosis modeltumor mutation burden

Identifiers

PMID34422808
PMCPMC8377503
OpenAlexW3192540747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.